Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$51.57
-0.8%
$49.59
$21.34
$58.40
$4.15B-0.151.06 million shs618,863 shs
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$12.50
+0.1%
$12.50
$8.05
$12.51
$799.18M1.391.45 million shs3.07 million shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$6.56
-6.0%
$6.67
$4.09
$17.24
$140.23M0.84282,861 shs189,465 shs
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$30.00
$29.59
$10.57
$30.04
$846.06M1468,738 shs1.72 million shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-0.83%-0.85%-2.62%+44.58%+114.88%
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.00%0.00%0.00%0.00%+69.08%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-6.02%-16.86%-17.48%+39.87%-55.07%
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
0.00%+0.94%+1.39%+3.20%+105.34%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.396 of 5 stars
3.51.00.04.71.40.80.0
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.6156 of 5 stars
1.00.00.04.50.01.70.6
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.9118 of 5 stars
3.41.00.04.72.72.50.0
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
1.8619 of 5 stars
1.02.00.82.62.61.70.0
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$82.5059.98% Upside
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.00
Hold$12.25-1.96% Downside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.80
Moderate Buy$18.00174.39% Upside
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
2.00
Hold$22.00-26.67% Downside
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ENTA, TRIL, AKRO, CDMO, and RDUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00
5/27/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$63.00 ➝ $64.00
5/13/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $78.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$139.91M5.71$0.15 per share80.92$3.02 per share4.14
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$64.46M2.18N/AN/A$6.08 per share1.08
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$2.74B0.31$0.73 per share40.96$18.73 per share1.60
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
-$266.41M-$3.60N/AN/A-3.69%-15.73%-6.01%N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest ENTA, TRIL, AKRO, CDMO, and RDUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$0.95N/AN/AN/AN/AN/A
8/4/2025Q3 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.10N/AN/AN/A$16.21 millionN/A
7/1/2025Q3 2025
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
-$0.87-$0.39+$0.48-$0.59$725.30 million$726.99 million
5/12/2025Q1 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$1.01$0.90+$1.91$0.90N/AN/A
5/12/2025Q2 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$0.752.50%N/AN/A N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A

Latest ENTA, TRIL, AKRO, CDMO, and RDUS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/26/2025
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
quarterly$0.18752.53%7/21/20257/21/20258/4/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.03
16.80
16.80
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.58
1.30
0.92
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
5.29
5.29
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
0.85
1.85
0.97
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.72 million74.08 millionOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
32063.96 million62.01 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16021.38 million18.41 millionOptionable
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
3,01128.20 million26.82 millionOptionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

Recent News About These Companies

Trillium Therapeutics Stock Price History
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$51.57 -0.43 (-0.83%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$51.53 -0.04 (-0.08%)
As of 07/11/2025 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Avid Bioservices stock logo

Avid Bioservices NASDAQ:CDMO

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$6.56 -0.42 (-6.02%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$6.56 0.00 (-0.08%)
As of 07/11/2025 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Radius Recycling stock logo

Radius Recycling NASDAQ:RDUS

$30.00 0.00 (0.00%)
Closing price 07/10/2025 06:09 PM Eastern
Extended Trading
$30.00 0.00 (0.00%)
As of 07/10/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Radius Recycling, Inc. recycles ferrous and nonferrous metal, and manufactures finished steel products worldwide. The company acquires, processes, and recycles salvaged vehicles, rail cars, home appliances, industrial machinery, manufacturing scrap, and construction and demolition scrap. It offers recycled ferrous metal, a feedstock used in the production of finished steel products; and nonferrous products, including mixed metal joint products recovered from the shredding process, such as zorba, zurik, aluminum, copper, stainless steel, nickel, brass, titanium, lead, and high temperature alloys. The company also procures salvaged vehicles and sells serviceable used auto parts from these vehicles through its retail self-service auto parts stores. In addition, it produces various finished steel products using ferrous recycled metal and other raw materials, as well as semi-finished goods, which include billets; and finished goods consisting of rebar, coiled rebar, wire rods, merchant bars, and other specialty products. Further, the company sells catalytic converters to specialty processors that extract the nonferrous precious metals, including platinum, palladium, and rhodium; and ferrous and nonferrous recycled metal products to steel mills, foundries, refineries, smelters, wholesalers, and recycled metal processors, as well as finished steel customers, such as steel service centers, construction industry subcontractors, steel fabricators, wire drawers, and major farm and wood products suppliers. It also provides recycling and related services, including scrap brokerage, certified destruction, automotive parts recycling, railcar dismantling, and reverse logistics under 3PR brand name. Radius Recycling, Inc. was formerly known as Schnitzer Steel Industries, Inc. and changed its name to Radius Recycling, Inc. in January 2024. Radius Recycling, Inc. was founded in 1906 and is headquartered in Portland, Oregon.

Trillium Therapeutics stock logo

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.